Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement
The Food and Drug Administration (FDA or Agency) is announcing year five of the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP). This program facilitates the expedited CMC development of products under an investigational new drug application (IND) based on the anticipated clinical benefit of earlier patient access to the products. FDA has implemented this pilot program to assist with CMC readiness for products regulated by both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) that have accelerated clinical development timelines. To accelerate CMC development and facilitate CMC readiness, the pilot features increased communication between FDA and sponsors and explores the use of science- and risk-based regulatory approaches, as applicable. This notice outlines the eligibility criteria and process for submitting a request to participate in the pilot.
Related coverage
- Agency Information Collection Activities; Court-Ordered Refunds Under the International Emergency Economic Powers Act Worksheet
- Notice To Reestablish the Transit Advisory Committee for Safety Charter
- Potential Designations of the Investment Banking Representative License (Series 79) and the Research Analyst License (Series 86 and Series 87) as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of U.S. Certified Public Accountant License as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of Certified Financial Planner Certification as Qualifying Natural Persons for Accredited Investor Status
- Potential Designation of Passage of an Accredited Investor Exam To Be Developed by FINRA as Qualifying Natural Persons for Accredited Investor Status